# TQB2825

Source: https://onco.cc/drugs/tqb2825/  
OnCo record `tqb2825` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TQB2825 is an experimental bispecific antibody from Chia Tai Tianqing Pharmaceutical in phase 2 trials for diffuse large B-cell lymphoma, aimed at CD20 and CD3.

## Summary

TQB2825 is a bispecific antibody developed by Chia Tai Tianqing Pharmaceutical and Shanghai Chia Tai Tianqing Pharmaceutical Technology Development. Its targets are CD20 and CD3 (the sponsor names CD3 x CD20). ClinicalTrials.gov describes the intervention as: Drug: TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection; Other Name: Gemcitabine Hydrochloride for Injection, Zefei; Oxaliplatin for Injection, Aihen TQB2825 injection is Cluster of Differentiation 3 (C. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in diffuse large B-cell lymphoma. The largest, NCT06829771, plans to enrol 90 participants with primary completion was scheduled for 2026-05 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: bispecific antibody
- Mechanism: Bispecific antibody directed at CD20 and CD3, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of TQB2825: https://clinicaltrials.gov/search?intr=TQB2825

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- targets: [CD20](https://onco.cc/targets/cd20/), [CD3](https://onco.cc/targets/cd3/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)
- trials: [Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma](https://onco.cc/trials/nct06829771/), [Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma](https://onco.cc/trials/nct06854445/)

---
JSON: https://onco.cc/api/v1/entities/tqb2825.json